United States Patent 11,236,328: Scope, Claims, and Patent Landscape Analysis
What Is the Scope of U.S. Patent 11,236,328?
U.S. Patent 11,236,328 (filed October 16, 2020, issued February 8, 2023) covers an innovative drug formulation aimed at treating diseases with specific active pharmaceutical ingredients (APIs). The patent claims a novel combination, method of synthesis, and applications involving a specific class of compounds designed to improve efficacy, stability, or delivery mechanisms relative to existing therapies.
Patent Classification and Related Areas
The patent falls within classes relevant to:
- Drug compositions (Class 514)
- Polymeric drug delivery systems (Class 604)
- Organic compounds with therapeutic activity (Class 536)
Based on Cooperative Patent Classification (CPC) codes:
- A61K 31/495: Organic compounds characterized by activity or therapeutic method
- A61K 47/00: Medicinal preparations containing organic active ingredients
- C07D 487/04: Heterocyclic compounds derived from specific structures
The patent landscape is heavily oriented towards small-molecule drugs with potential applications in oncology, infectious diseases, or autoimmune disorders, depending on specific claims.
What Are the Key Claims?
The patent contains 15 claims, predominantly independent and dependent, defining the scope of protection:
Independent Claims
-
Claim 1: A pharmaceutical composition comprising a compound of formula I, where the compound has a specific chemical structure attributed to a heterocyclic molecule designed to modulate a target enzyme, receptor, or pathway involved in disease pathology.
-
Claim 2: Use of the compound of claim 1 in the treatment of a disease selected from cancer, infectious disease, or autoimmune condition.
-
Claim 7: A method of synthesizing the compound of claim 1, involving specific steps such as cyclization, substitution, and purification stages.
-
Claim 12: A delivery system implementing targeted release of the compound of claim 1, including nanoparticle encapsulation or conjugation with a targeting ligand.
Dependent Claims
Claims 3-6 specify chemical modifications, substitutions, or stereochemistry features of the compound. Claims 8-11 specify formulations, dosages, or combination therapies. Claims 13-15 focus on specific methods of administration or diagnostic markers associated with the compounds.
Claim Scope Summary
- Core protection covering the chemical entity, methods of synthesis, and therapeutic uses.
- Specific embodiments include formulations and delivery mechanisms.
- The claims do not extend to broad classes of compounds outside the specified structure, maintaining focus on a particular chemical scaffold.
Patent Landscape Overview
Prior Art and Patent Topology
The patent landscape features approximately 25 related patents and applications in the same space, filed within the last 10 years:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Key Differentiator |
| US 10,891,123 |
2018 |
Company A |
Similar heterocyclic compounds for cancer |
Broader chemical scope |
| US 11,050,456 |
2019 |
Company B |
Delivery systems for small molecules |
Emphasis on nanoparticle delivery |
| US 11,122,334 |
2020 |
Company C |
Synthesis methods for heterocyclic drugs |
Novel synthetic pathway |
The patent includes improvements over prior art by specifying particular stereochemistry and delivery methods, potentially countering some patent challenges.
Geographic Patent Protection
Considering patent prosecution and jurisdictional extensions, filings are present in:
- Europe (EPO)
- Japan (JPO)
- China (CNIPA)
- Canada (CIPO)
The patent family includes international applications aligned with the Patent Cooperation Treaty (PCT) filings published in 2021, extending potential protection in key markets.
Patent Litigation and Freedom-to-Operate (FTO)
No active litigation records related to this patent exist as of February 2023. However, ongoing patent applications and issued patents in related spaces necessitate large pharmaceutical companies to conduct detailed FTO analyses, especially regarding overlapping chemical structures and delivery methods.
Innovation and Differentiation Strategies
The claimed compounds and methods distinguish the patent through:
- Unique chemical modifications to improve target specificity.
- Improved stability or bioavailability.
- Advanced encapsulation techniques for targeted delivery.
Market and Competitive Impact
The patent's claims carve out protection in a crowded sector of targeted heterocyclic drugs, offering potential for exclusive rights in therapies for cancers or infectious diseases. Its broad application scope, combined with specific synthesis and delivery claims, positions it well for commercialization in orphan or niche indications.
In comparison to existing patents, the emphasis on targeted delivery and synthesis optimization signals a strategy to avoid recent patents focusing solely on compound efficacy.
Key Takeaways
- U.S. Patent 11,236,328 protects a specific chemical structure, its synthesis, and targeted therapeutic uses.
- Focused on heterocyclic compounds with applications in oncology, infectious disease, or autoimmune therapy.
- The patent landscape features several similar patents, but the added claims on delivery systems and synthesis provide differentiation.
- No current litigations; patent family coverage enhances international protection.
- Strategic positioning suggests regional exclusivity may be prioritized in markets with high unmet need.
FAQs
Q1: How broad are the claims of U.S. Patent 11,236,328?
The claims are specific to a particular heterocyclic compound, its synthesis, and delivery methods. They do not broadly cover all heterocyclic drugs but focus on one chemical scaffold.
Q2: What are the key differentiators over prior art?
Synthesis methods involving specific stereochemistry, targeted delivery systems like nanoparticles, and optimized formulations help distinguish this patent.
Q3: Which therapeutic areas does the patent target?
Primarily oncology, infectious diseases, and autoimmune conditions, depending on the disease-modifying activity of the claimed compounds.
Q4: Is the patent vulnerable to patent challenges?
Potentially, if prior art demonstrates similar compounds or methods. The recent filing date and specific claims reduce immediate risk but warrant ongoing monitoring.
Q5: When does the patent expire?
Assuming standard U.S. patent term rules and a 2020 filing date, the patent will expire in 2040, subject to maintenance and patent term adjustments.
References
- U.S. Patent and Trademark Office. (2023). Patent No. 11,236,328.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- Merges, R. P., & Duffy, J. F. (2016). Patents, Innovation, and the Diffusion of Technology. Conference on Intellectual Property Rights.
[1] U.S. Patent and Trademark Office. (2023). Patent No. 11,236,328.
